HCP Disclaimer

If you are a parent or carer please visit www.nutramigen.co.uk/parent

This website is intended for healthcare professionals and contains information about Mead Johnson Nutrition special infant formulas.

Important Notice: Breast feeding provides the best nutrition for babies. Mead Johnson special formulas are intended for bottle-fed infants and are Food for Special Medical Purposes (FSMPs) and must be used under medical supervision.

This website relies on the use of cookies to function correctly. This includes a cookie to recognise that you have agreed to accept cookies, analytic cookies that help us analyse use of the website for improving the content, and social sharing cookies that allow users to share content on the web more easily. By clicking “accept” below you agree to allow us to place cookies into your computer. For more information about how we use cookies, please read our privacy policy.

By proceeding you confirm you are a healthcare professional.

Not a HCP?

LIPIL

Clinically proven to support brain and eye development1-3 product-lipil.jpg

The Nutramigen range of products is the first to contain LIPIL – a unique blend of DHA and ARA (omega-3 and omega-6 fatty acids) at optimum levels to support brain and eye development.1–3 Nutramigen is the only eHF to contain 0.3% DHA, the level endorsed by the EFSA to improve visual acuity at 12 months.4

nut-differrence-lipil.png

LIPIL improves cognitive development

Infants receiving formula supplemented with LIPIL performed significantly better in tests of problem-solving ability than infants receiving unsupplemented formula at age 9 months.2

  • More successful task completions
  • More goal-oriented behaviour

nut-difference-lipil-1.png

LIPIL improves visual acuity

Infants receiving formula supplemented with 0.3% DHA showed significant increases in visual acuity at age 12 months compared to those receiving a formula without DHA.1,3

nut-difference-lipil-2.png

LIPIL has been proven to contain the optimum level of DHA for improved visual development in a recent study.5 No improvements were observed with levels below 0.3%, and higher levels gave no additional benefit.5

Show references
  1. Birch EE, Carlson SE, Hoffman DR et al. The DIAMOND (DHA Intake And Measurement Of Neural Development) Study: a double-masked, randomized controlled clinical trial of the maturation of infant visual acuity as a function of the dietary level of docosahexaenoic acid. Am J Clin Nutr 2010;91:848-59.

  2. Drover J, Hoffman DR, Castaneda YS et al. Three randomized controlled trials of early long-chain polyunsaturated Fatty Acid supplementation on means-end problem solving in 9-month-olds. Child Dev 2009;80:1376-84.

  3. Morale SE, Hoffman DR, Castaneda YS et al. Duration of long-chain polyunsaturated fatty acids availability in the diet and visual acuity. Early Hum Dev 2005;81:197-203.

  4. European Commission. COMMISSION REGULATION (EU) No 440/2011 of 6 May 2011 on the authorisation and refusal of authorisation of certain health claims made on foods and referring to children's development and health. Official Journal of the European Union 2011;L119:4-9.

  5. Birch EE, Khoury JC, Berseth CL et al. The impact of early nutrition on incidence of allergic manifestations and common respiratory illnesses in children. J Pediatr 2010;156:902-6, 906.